linjc16/ctgov huggingface dataset:
Asphyxia Associated Metabolite Biomarker Investigation 2

Study Overview
=================
Brief Summary
-----------------
Follow-up of participants of AAMBI1 study at age of at least 2 years. AAMBI1(ClinicalTrials.gov ID: NCT03354208): Verification of biomarkers in a human population for their ability to diagnose the severity of neonatal asphyxia. These biomarkers linked to asphyxia have been identified in animal studies.

Detailed Description
-----------------
Follow-Up on neuro-developmental status of Study participants of AAMBI1. AAMBI1(ClinicalTrials.gov ID: NCT03354208): The aim of the study is to verify the application of combinations of several laboratory parameters in early postnatal blood samples, for identification of infants, who will suffer from early abnormal neonatal neurological outcome, in a population at risk. The population at risk is defined as term and late preterm (>36 weeks of gestation) human infants following perinatal hypoxia-ischemia with or without postnatal resuscitation.

Official Title
-----------------
Verification of Biomarkers to Examine Neonatal Asphyxia-induced Hypoxic-ischemic Encephalopathy Study on Neuro-developmental Follow-up at 2 Years A Prospective Multicenter Observational Study for Development of a Diagnostic Test

Conditions
-----------------
Birth Asphyxia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants previously enrolled in the AAMBI1 study Exclusion Criteria: Missing valid written informed parental consent

Ages Eligible for Study
-----------------
Minimum Age: 22 Months
Maximum Age: 48 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Infants enrolled in AAMBI1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Participants with normal neuro-developmental status | All infants with normal neuro-developmental status | up to 42 month age | 
| Participants with potentially abnormal neuro-developmental status | All infants who do not fulfill outcomes 1, 3 or 4 | up to 42 month age | 
| Participants with abnormal neuro-developmental status - HIE | Presence of adverse 2 years neuro-developmental outcome likely attributable to perinatal hypoxic-ischemic brain injury | up to 42 month age | 
| Participants with abnormal neuro-developmental status - non-HIE | Presence of adverse 2 years neuro-developmental Outcome not attributable to perinatal hypoxic-ischemic brain injury | up to 42 month age | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biomarkers, asphyxia, Hypoxic ischemic encephalopathy
Edaravone in the Treatment of Aquaporin-4 Antibody-positive Optic Neuritis

Study Overview
=================
Brief Summary
-----------------
Edaravone showed a good effect on promoting remyelination and protecting axons in NMOSD animals. The investigators hypothesize that edaravone can inhibit axonal damage in patients with aquaporin-4 antibody-positive optic neuritis.

Official Title
-----------------
Edaravone in the Treatment of Aquaporin-4 Antibody-positive Optic Neuritis

Conditions
-----------------
Optic Neuritis

Intervention / Treatment
-----------------
* Drug: Edaravone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis Patients with a first episode of optic neuritis in either eye First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone Exclusion Criteria: Myopia over 6 diopters Refractive media opacity affecting assessment of retinal layers and/or visual acuity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Edaravone<br> | Drug: Edaravone<br>* Edaravone injection 30mg three times a day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best-corrected visual acuity | Best-corrected visual acuity will be measured by Illiterate Echart. | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ganglion cell-inner plexiform layer | Ganglion cell-inner plexiform layer will be measured by optical coherence tomography. | 18 months | 
| Peripapillary retinal nerve fiber layer | Peripapillary retinal nerve fiber layer will be measured by optical coherence tomography. | 18 months |
Anesthetic & Surgical Protocol for Emergency Surgeries During the Era of COVID-19

Study Overview
=================
Brief Summary
-----------------
A protocol applied during anesthesia and surgical interventions for patients with emergency surgical conditions during the era of COVID-19 disease

Detailed Description
-----------------
All COVID-19 patients who were admitted to emergency departments presenting with emergency surgical conditions were evaluated for assurance of having COVID-19 disease. Then, the appropriate anesthetic procedure was applied and the appropriate surgical intervention was performed.

Official Title
-----------------
Protocol for Anesthesia for Emergency Surgery

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Procedure: Emergency surgical procedures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Assured diagnosis of COVID-19 by RT-PCR Exclusion Criteria: No
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: All patients presenting with surgical emergency
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Successful outcome<br>It will include the anesthetic and operative data and the incidence of intraoperative or postoperative complication | Procedure: Emergency surgical procedures<br>* COVID-19 patients who had presented to the Emergency Department were evaluated for their emergency surgical conditions and were managed appropriately<br>* Other names: Total intravenous anesthesia;|
| Active Comparator: Complicated outcome<br>It will include the anesthetic and operative data and the incidence of intraoperative or postoperative complication | Procedure: Emergency surgical procedures<br>* COVID-19 patients who had presented to the Emergency Department were evaluated for their emergency surgical conditions and were managed appropriately<br>* Other names: Total intravenous anesthesia;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaire | This questionnaire was designed to assess the satisfaction of the anesthetist in-charge and the surgeon by the applied protocol to manage COVID-19 patients | Up to two days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physiologic assessment | estimation of systolic and diastolic blood pressures of patients during and after surgery | Up to one day | 
| Surgical follow-up | Postoperative assessment of wounds and drainage tube, if any, and to determine the success of the procedure or the development of complications | Up to 10 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, Anesthesia, Surgery, Outcomes
Respiratory Complications Among Living Liver-donors

Study Overview
=================
Brief Summary
-----------------
Recently, there are increasing reports about pulmonary complications within living liver donors postoperatively. In this retrospective study, the investigators will highlight the risk factors and incidence of pulmonary complication among living liver-donors in our center.

Official Title
-----------------
Respiratory Complications Among Living Liver-donors: a Single Center Observational Retrospective Study

Conditions
-----------------
Complication of Anesthesia

Intervention / Treatment
-----------------
* Procedure: Collection of data


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Excellent general physical and mental condition, Free of chronic disease or Previous major abdominal surgery, Body mass index (BMI) <28, ABO blood group identical to recipients and Negative for hepatitis B, C and human immunodeficiency viruses (HIV). Exclusion Criteria: ASA physical status> II, BMI>28, Psychiatric or mental retardation, pregnant and nursing women or Patients with significant laboratory abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Collection of data|The investigators will retrieve retrospectively the medical record of donors who underwent hepatic lobectomy for liver transplantation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of participants with postoperative respiratory complications | Respiratory complications as pulmonary embolism, pleural effusion, pneumothorax, pneumonia, atelectasis, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and transfusion-related acute lung injury (TRALI) will be considered when they are clinically evident. | an average period of 3 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The average of ICU stay among patients | It is defined as time period from entry to ICU till discharge to the ward | an average period of 3 year | 
| The average of hospital stay among patients | It is defined as time period elapsed from discharge to the ward till leaving the hospital | an average period of 3 year |
A Comparison of the Estimates of Fuwai and Reynolds Risk Model

Study Overview
=================
Brief Summary
-----------------
There are many risk prediction models. And their estimates are different. This study aimed to investigate the differences between the estimates of Fuwai and Reynolds risk model in Chinese, and investigate the reason for the differences.

Detailed Description
-----------------
The participants will examined for cardiovascular risk factors, and their cardiovascular risks will be calculated based on the values of the risk factors using cardiovascular risk models. The estimates of different risk models will be compared, and the levels of traditional risk factors will be adjusted in order to evaluate the impacts of uncommon risk factors such as social and genetic risk factors.

Official Title
-----------------
A Comparison of the Estimates of Fuwai and Reynolds Risk Model

Conditions
-----------------
Coronary Heart Disease and Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults - Exclusion Criteria: with coronary heart disease -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| participants<br>healthy adults without stroke and coronary heart disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiovascular risk | The cardiovascular risk is the probability of the occurrence of coronary heart disease and stroke. The cardiovascular risk is calculated by risk prediction models based on the patient's risk factors. | 1 day |
Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the safety and effect of MK0759 in relieving neuropathic pain as experienced by patients with postherpetic neuralgia (PHN).

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Explore the Safety and Preliminary Efficacy of Oral MK0759 in the Treatment of Postherpetic Neuralgia

Conditions
-----------------
Neuralgia, Postherpetic

Intervention / Treatment
-----------------
* Drug: MK0759


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 to 85; diagnosis of postherpetic neuralgia with pain having persisted at least 6 months; dissatisfied with current regimen of pain control; able to complete study questionnaires, patient diary, and comply with daily study medication Exclusion Criteria: Women of childbearing potential; history or evidence of a condition that, in the opinion of the investigator, may interfere with the study interpretation (e.g., diabetic neuropathy or fibromyalgia) or pose undue risk to undergo the course of medication required by the study (e.g., unstable heart disease, morbid obesity, kidney or liver disease).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0759|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain intensity recorded by the patient each evening using an 11-point Likert scale (0=no pain to 10=pain as bad as you can imagine). |  | Duration of Treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety; Patient Global Impression of Change assessed at the end of each treatment period. |  | Duration of Treatment |
Epidemiologic, Laboratory, and Clinical Characterization of Individuals With Cancer.

Study Overview
=================
Brief Summary
-----------------
Environmental and genetic factors may play a role in the progression of cancer. The goal of this project is to establish a series of cross-sectional / case-control studies to evaluate risk factors of cancer in China.

Detailed Description
-----------------
This study is designed to investigate the epidemiologic, genetic, laboratory and clinical characterization of individuals with cancer (gastric, colorectal, esophageal, liver, prostate, lung, breast and endometrial cancer, etc.). We will accrue approximately 1600 patients as experimental group. The control group consists of subjects who will be confirmed without cancer. We will explore the environmental (including family history, life style, diet, physical activity, neuropsychological functioning，plasma levels of oxidative stress factors, angiogenic factors, and tumor markers, etc.) and genetic (including oxidative stress factors and angiogenic factors, etc.) risk factors. We will study the association between various environmental risk factors with the clinical characterization and correlation between the genetic polymorphisms and the presence of various cancer.

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: This is a study only of Chinese. Subjects will be allowed to participate if they self-identify as Chinese. The age range of the participants will be between 18 and 89 years. Individuals with cancer (gastric, colorectal, esophageal, liver, prostate, lung, breast and endometrial cancer, etc.) will be allowed to participate. To participate in the study as the control, subjects should be confirmed without cancer. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cancer,Risk factors
Recovery From Anesthesia After Robotic Assisted Radical Cystectomy

Study Overview
=================
Brief Summary
-----------------
Robot-assisted radical cystectomy (RARC) requires specific surgical conditions: steep Trendelenburg position, prolonged pneumoperitoneum, effective neuromuscular block until the final stages of surgery. The aim of this study was to evaluate the quality of awakening in two groups of patients undergoing different combinations of curarization/reversal.

Official Title
-----------------
Recovery From Anesthesia After Robotic Assisted Radical Cystectomy. Two Different Reversal of Neuromuscular Blockade

Conditions
-----------------
Anesthesiology Management

Intervention / Treatment
-----------------
* Drug: Sugammadex Injectable Product
* Drug: Neostigmine, Atropine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA (american society of anesthesiologists) score ≤ III Patients underwent robotic assisted cystectomy Exclusion Criteria: Cerebrovascular disease BMI (body mass index) ≥ 30

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sugammadex<br>The patients received sugammadex as neuromuscular blockade reversal | Drug: Sugammadex Injectable Product<br>* Patients receive sugammadex at the end of the surgery<br>|
| Active Comparator: Standard<br>The patients received neostigmine + atropine as neuromuscular blockade reversal | Drug: Neostigmine, Atropine<br>* Patients receive neostigmine+atropine at the end of the surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to discharge from recovery room | Time between reversal administration and discharge from the recovery room | Up to 240 Minutes After recovery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Curare, Robotic surgery
Morbidity After Surgical Treatment of Perforated Ulcer

Study Overview
=================
Brief Summary
-----------------
The main objective of our study is to identify the risk factors for postoperative morbidity after surgical treatment of Perforated peptic ulcer

Detailed Description
-----------------
the investigators conducted a retrospective study of 116 patients, operated on for a perforated peptic ulcer, carried out in the General Surgery Department of Taher Sfar University Hospital in Mahdia over a period of 11 years 6 months.

Official Title
-----------------
Postoperative Morbidity Risk Factors After Surgical Treatment of Perforated Peptic Ulcer: a Retrospective Study of 116 Patients

Conditions
-----------------
Peptic Ulcer Perforation

Intervention / Treatment
-----------------
* Procedure: Primary closure with or without omental grafting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who underwent surgery for a perforated peptic ulcer in the General Surgery Department of Taher Sfar University Hospital in Mahdia, between January 1, 2010, and June 1, 2021, were included in this study. Exclusion Criteria: patients who have medical treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Primary closure with or without omental grafting|Primary closure with or without omental grafting|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative medical or surgical complication | the investigators determined the number of Participants With postoperative medical or surgical complication after surgical treatement of perforated ulcer | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postoperative complication, Risk factor
Vascular Endothelial Growth Factor Levels in Patients Undergoing Embryo Transfer

Study Overview
=================
Brief Summary
-----------------
Assessing the relationship between the VEGF levels in blood and the IVF protocol

Detailed Description
-----------------
The investigators are assessing the VEGF levels in the blood in IVF patients undergoing different protocols

Official Title
-----------------
Vascular Endothelial Growth Factor Levels in Patients Undergoing Embryo Transfer

Conditions
-----------------
Reproductive Techniques

Intervention / Treatment
-----------------
* Other: NO intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing IVF - Exclusion Criteria: Women with any malignancy Patients request to be withdrawn

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| fresh<br>NO INTERVENTION | Other: NO intervention<br>* NO INTERVENTION<br>|
| Frozen embro transfer natural<br>NO INTERVENTION | Other: NO intervention<br>* NO INTERVENTION<br>|
| Frozen embro transfer hormonal<br>NO INTERVENTION | Other: NO intervention<br>* NO INTERVENTION<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| vascular endothelial growth factor LEVELS | levels of vascular endothelial growth factor in blood | 5 days |